Plasma-based antigen persistence in the post-acute phase of COVID-19

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(6), P. e345 - e347

Published: April 8, 2024

Language: Английский

---

Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID

Communications Medicine, Journal Year: 2024, Volume and Issue: 4(1)

Published: July 11, 2024

Although the COVID-19 pandemic has persisted for over 3 years, reinfections with SARS-CoV-2 are not well understood. We aim to characterize reinfection, understand development of Long COVID after and compare severity reinfection initial infection.

Language: Английский

---

A mini review of reinfection with the SARS‐CoV‐2 Omicron variant

Health Science Reports, Journal Year: 2024, Volume and Issue: 7(4)

Published: April 1, 2024

COVID-19 has caused severe morbidity and mortality worldwide. After the end of dynamic zero-COVID policy in China December, 2022, concerns regarding reinfection were raised while little was known due to lack surveillance data this country.

Language: Английский

---

Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: April 24, 2024

Under-reporting of COVID-19 and the limited information about circulating SARS-CoV-2 variants remain major challenges for many African countries. We analyzed infection dynamics in Addis Ababa Jimma, Ethiopia, focusing on reinfection, immunity, vaccination effects. conducted an antibody serology study spanning August 2020 to July 2022 with five rounds data collection across a population 4723, sequenced PCR-test positive samples, used available test positivity rates, constructed two mathematical models integrating this data. A multivariant model explores variant identifying wildtype, alpha, delta, omicron BA.4/5 as key population, cross-immunity between variants, revealing risk reductions 24% 69%. An antibody-level predicts slow decay leading sustained high levels. Retrospectively, increased early might have substantially reduced infections during delta waves considered group individuals, though further now seems less impactful.

Language: Английский

---

Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis

Journal of Global Health, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 7, 2025

Abstract Background Our previous systematic review estimated the cumulative incidence of SARS-CoV-2 reinfections as 1.16% (95% CI = 1.01–1.33%) during pre-Omicron period. The Omicron variant that emerged in November 2021 was significantly genetically distinct from variants and thus, more transmissible posed an increased risk population. We, therefore, conducted a fresh meta-analysis to estimate reinfection burden Methods We searched CINAHL, Medline, Global Health, Embase, WHO COVID-19 October 2023 for studies reporting quality included assessed using Joanna Briggs Institute checklists. Random effects meta-analyses were incidence, requirement hospitalisation reinfections. Symptomatic severity case fatality rates analysed narratively. Results Thirty-six included. period 3.35% 1.95–5.72%) based on data 28 studies. higher 18–59-year-old adults (6.62% 3.22–13.12%)) compared other age groups health care workers (9.88% 5.18–18.03%)) general population (2.48% 1.34–4.54%)). about 1.81% 0.18–15.87%) reinfected cases required limited highly variable data. Conclusions There generally less severe However, disease long-term outcomes. Registration PROSPERO: CRD42023482598.

Language: Английский

---

Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(2)

Published: Jan. 3, 2024

Abstract Background We previously conducted a phase 2a randomized placebo-controlled trial of 40 subjects to assess the efficacy and safety dupilumab use in people hospitalized with coronavirus disease 2019 (COVID-19) (NCT04920916). Based on our preclinical data suggesting that downstream pulmonary dysfunction COVID-19 induced type 2 inflammation, we contacted patients from study at 1 year for assessment post-COVID-19 conditions. Methods Subjects after treatment underwent function tests, high-resolution computed tomographic imaging, symptom questionnaires, neurocognitive assessments, serum immune biomarker analysis, subject survival also monitored. The primary outcome was proportion abnormal diffusion capacity carbon monoxide (DLCO) or 6-minute walk test (6MWT) 1-year visit. Results Of those survivors who consented visits (n = 16), had originally received were less likely than placebo have an DLCO 6MWT (Fisher exact P .011; adjusted .058). As secondary endpoint, saw 16% group died by compared 38% group, though this not statistically significant (log-rank .12). did find differences testing, symptoms, chest tomography between groups but observed larger reduction eotaxin levels dupilumab. Conclusions In observational study, during acute hospitalization reduced 6MWT, nonsignificant trend toward mortality placebo.

Language: Английский

---

Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19

Pathogens, Journal Year: 2024, Volume and Issue: 13(12), P. 1109 - 1109

Published: Dec. 15, 2024

Antibody-dependent enhancement (ADE) is a phenomenon in which antibodies enhance subsequent viral infections rather than preventing them. Sub-optimal levels of neutralizing individuals infected with dengue virus are known to be associated severe disease upon reinfection different serotype. For Severe Acute Respiratory Syndrome Coronavirus type-2 infection, three types ADE have been proposed: (1) Fc receptor-dependent infection cells expressing receptors, such as macrophages by anti-spike antibodies, (2) receptor-independent epithelial and (3) cytokine production anti-nucleocapsid antibodies. This review focuses on the induced examining its potential role COVID-19 during contribution post-acute sequelae COVID-19, i.e., prolonged symptoms lasting at least months after acute phase disease. We also discuss protective effects recently identified that neutralize Omicron variants.

Language: Английский

---

Perceived social support and self-stigma as factors of COVID-19 booster vaccination behavior and intention via cognitive coping and emotion regulation among people infected with COVID-19 in Hong Kong

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 18, 2025

Abstract Background It is imperative to promote behavior/intention of taking up booster COVID-19 vaccination (BI-BV) among people who have ever contracted (PECC). The aims were investigate the prevalence BI-BV and its associations with perceived social support. Guided by stress coping theory, we tested mediators between support via self-stigma, active coping, maladaptive emotion regulation (rumination catastrophizing). Methods A random population-based telephone survey was conducted adult PECC having completed primary series prior diagnosis; 230 participants interviewed from June August 2022 during fifth (last) major outbreak in Hong Kong. independent variables logistic regression analysis. structural equation model (SEM) indirect effects latent variable BI-BV. Results 62.2%. associated age, marital status, full-time employment, chronic disease status. analysis found that positively (ORc = 1.31, 95% CI: 1.12– 1.54), 1.40, 1.10– 1.79), rumination 1.75, 1.13– 2.70), catastrophizing 3.12, 1.49– 6.51) negatively self-stigma 0.80, 0.72– 0.88). In SEM analysis, positive association fully mediated: 1) (β 0.07, 0.03– 0.14), 2) 0.06, 0.02– 0.12), 3) then 0.01, 0.002– 0.04). Two these paths involved coping. involving all non-significant. Conclusions Perceived BI-BV, mediated serially but not maladaptation. data supported cognitive explaining Interventions promoting may consider modifying observed significant factors. Future longitudinal studies are warranted confirm findings.

Language: Английский

---

COVID-19 Symptoms by Immunity Status and Predominant-Variant Period among US Blood Donors

Open Forum Infectious Diseases, Journal Year: 2025, Volume and Issue: 12(5)

Published: March 26, 2025

Abstract Background Amid changing variant and immunity landscapes since early in the coronavirus disease 2019 (COVID-19) pandemic, common COVID-19 symptoms need better understanding relation to prior or infecting variant. Methods American Red Cross blood donors were surveyed during February–April 2022 about vaccinations symptomatic severe acute respiratory syndrome 2 (SARS-CoV-2) infections. Donations tested for anti-nucleocapsid antibodies inform infection history. Restricting analysis with survey-reported infections Omicron BA.1-predominant period (19 December 2021 through 19 March 2022), we used multivariable logistic regression compare by existing from vaccination. those no immunity, compared variant-predominant of their first reported (BA.1 vs before). Results Among 9505 a infection, (n = 1115), vaccination 5888), both 1738) less likely than without 764) report loss taste smell, lower tract, constitutional, gastrointestinal more upper tract symptoms. Stronger associations followed recent vaccination, vaccine doses. 8539 before this 7775). Conclusions Our data suggest that predominance redistributed toward presentations contributed decrease severity over time. These findings may identification high-immunity settings demonstrate additional benefits

Language: Английский

---

Self-Reported SARS-CoV-2 Infections among National Blood Donor Cohort, United States, 2020–2022

Emerging infectious diseases, Journal Year: 2025, Volume and Issue: 31(5)

Published: April 24, 2025

SARS-CoV-2 case surveillance in the United States did not distinguish first infections from reinfections. In a large blood donor cohort, self-reported and reinfections during 2020-2022 mirrored public health count surveillance, reinfection incidence peaked 2022. Blood data could aid emerging infectious disease surveillance.

Language: Английский

---